Navigation Links
Diplomat Announces 2nd Quarter Financial Results

FLINT, Mich., Aug. 7, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2017.  All comparisons, unless otherwise noted, are to the quarter ended June 30, 2016.

Second Quarter 2017 Highlights include:

  • Revenue of $1,126 million, compared to $1,089 million, an increase of 3.5%
  • Total prescriptions dispensed of 220,000, compared to 241,000
  • Gross margin of 7.5% versus 7.6%
  • Gross profit per prescription dispensed of $371, compared to $339
  • Net income attributable to Diplomat of $3.6 million, compared to $8.5 million
  • Adjusted EBITDA of $25.2 million, compared to $29.6 million
  • Adjusted EBITDA margin of 2.2% versus 2.7%
  • EPS of $0.05 per diluted common share versus $0.13
  • Adjusted EPS of $0.25 versus $0.23
  • Phil Hagerman, CEO and Chairman of Diplomat, commented, "I'm very pleased with our solid second quarter results, which saw continued strength in oncology and infusion, up 25% and 20% year over year, respectively.  In the first half of 2017, a transition year for Diplomat, we have made promising strides in our, higher margin, tuck-in acquisition strategy in infusion, as well as with our managed care strategy.  In addition, we are seeing customers start to embrace our expanded service division. Finally, I'm thrilled to announce that Joel Saban has joined us as President of Diplomat, bringing years of industry experience, which I believe will be a tremendous asset to our company."

    Second Quarter Financial Summary:Revenue for the second quarter of 2017 was $1,126 million, compared to $1,089 million in the second quarter of 2016, an increase of $38 million or 3.5%.  The increase was driven by approximately $83 million of revenue from our acquisitions, approximately $63 million from the impact of manufacturer price increases, and approximately $32 million from drugs that were new in the past year.  These increases were partially offset by a decrease due to contracts that were not renewed in 2017 as well as a decrease in the demand for hepatitis C drugs versus the prior year period.  Our revenue increase year over year, excluding the impact of the contract losses was approximately $160 million or 15%. 

    Gross profit in the second quarter of 2017 was $84.8 million and generated a 7.5% gross margin, compared to $83.3 million and 7.6% in the second quarter of 2016.  The gross margin decline in the quarter was primarily due to an increase in accrued direct and indirect remuneration ("DIR") fees versus what was accrued in the second quarter of 2016. 

    Selling, general, and administrative expenses ("SG&A") for the second quarter of 2017 were $80.0 million, an increase of $10.6 million, compared to $69.4 million in the second quarter of 2016.  Of this change, $7.2 million related to employee cost, including employee cost for our acquired entities.  The increased employee expense was attributable to the growth in our infusion and oncology business which is more clinically and administratively complex.  Also contributing to the SG&A expense increase was a $3.1 million increase in amortization expense from definite-lived intangible assets associated with our acquired entities.  We also experienced increases in other SG&A; including freight, insurance, and other miscellaneous expenses.  As a percentage of revenue, SG&A was 7.1% for the three months ended June 30, 2017, compared to 6.4% in the prior year period.  This increase is primarily attributable to the increase in acquisition related amortization and the increased operating complexity associated with both our acquisitions and new drugs.

    Net income attributable to Diplomat for the second quarter of 2017 was $3.6 million compared to $8.5 million in the second quarter of 2016.  This decrease was primarily driven by the revenue, gross profit, and SG&A explanations above, partially offset by a $4.7 million change in income taxes. Adjusted EBITDA for the second quarter of 2017 was $25.2 million compared to $29.6 million in the second quarter of 2016, a decrease of $4.5 million. 

    Earnings per share for the second quarter of 2017 was $0.05 per basic/diluted common share, compared to $0.13 per basic/diluted common share for the second quarter of 2016.  Diluted non-GAAP adjusted earnings per share ("Adjusted EPS") was $0.25 in the second quarter of this year compared to $0.23 in the second quarter of 2016.   

    2017 Financial Outlook For the full-year 2017, we are updating our previous financial guidance:

  • Revenue between $4.3 and $4.6 billion, versus the previous range of $4.3 and $4.7 billion
  • Net income attributable to Diplomat between $10 and $16 million, versus the previous range of $6.5 and $15.5 million
  • Adjusted EBITDA between $97 and $103 million, versus the previous range of $95 and $103 million
  • Diluted EPS between $0.15 and $0.23, versus the previous range of $0.09 and $0.23  
  • Adjusted EPS between $0.71 and $0.79, versus the previous range of $0.54 and $0.70
  • Our EPS and Adjusted EPS expectations assume approximately 68,600,000 weighted average common shares outstanding on a diluted basis and a tax rate of 26%, versus the previous tax rate of 35% and 40% for the high and low of the range respectively, for the full year 2017, which could differ materially. 

    Earnings Conference Call InformationAs previously announced, the Company will hold a conference call to discuss its second quarter performance this evening, August 7, 2017, at 5:00 p.m. Eastern Time.  Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 877-201-0168 (or 647-788-4901 for international callers) and referencing participant code 51641230 approximately 15 minutes prior to the call.  A live webcast and audio file of the conference call will be available on the investor relations section of the Company's website for approximately 90 days at

    About DiplomatDiplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit

    Non-GAAP InformationAdjusted EPS adds back, net of income taxes, the impact of all merger and acquisition related expenses, including amortization of intangible assets, the change in fair value of contingent consideration, as well as transaction-related costs.  We exclude merger and acquisition-related expenses from Adjusted EPS because we believe the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and such expenses can vary significantly between periods as a result of new acquisitions, full amortization of previously acquired intangible assets, or ultimate realization of contingent consideration.  Investors should note that acquisitions, once consummated, contribute to revenue in the periods presented as well as future periods and should also note that amortization and contingent consideration expenses may recur in future periods.  A reconciliation of Adjusted EPS, a non-GAAP measure, to EPS as prepared in accordance with accounting principles generally accepted in the United States ("GAAP") can be found below.

    We define Adjusted EBITDA as net income (loss) attributable to Diplomat before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuring and impairment charges, and certain other items that we do not consider indicative of our ongoing operating performance (which are itemized below in the reconciliation to net income (loss) attributable to Diplomat).  Adjusted EBITDA is not in accordance with, or an alternative to, GAAP.  In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles.  You should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in the presentation, and we do not infer that our future results will be unaffected by unusual or non-recurring items. 

    We consider Adjusted EBITDA and Adjusted EPS to be supplemental measures of our operating performance.  We present Adjusted EBITDA and Adjusted EPS because they are used by our Board of Directors and management to evaluate our operating performance.  Adjusted EBITDA is also used as a factor in determining incentive compensation, for budgetary planning and forecasting overall financial and operational expectations, for identifying underlying trends, and for evaluating the effectiveness of our business strategies.  Further, we believe they assist us, as well as investors, in comparing performance from period-to-period on a consistent basis.  Other companies in our industry may calculate Adjusted EBITDA and Adjusted EPS differently than we do and these calculations may not be comparable to our Adjusted EBITDA and Adjusted EPS metrics.  A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss) attributable to Diplomat can be found below.

    Forward Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include Diplomat's expectations regarding revenues, net income (loss) attributable to Diplomat, Adjusted EBITDA, EPS, Adjusted EPS, market share, the performance of acquisitions and growth strategies.  The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements.  These risks and uncertainties include: our ability to adapt to changes or trends within the specialty pharmacy industry; significant and increasing pricing pressure from third-party payors; the amount of direct and indirect remuneration fees, as well as the timing of assessing such fees and the non-transparent methodology used to calculate such fees; the outcome of material legal proceedings related to direct and indirect remuneration fees; our relationships with key pharmaceutical manufacturers; bad publicity about, or market withdrawal of, specialty drugs we dispense; a significant increase in competition from a variety of companies in the health care industry; our ability to expand the number of specialty drugs we dispense and related services; maintaining existing patients; revenue concentration of the top specialty drugs we dispense; our ability to maintain relationships with a specified wholesaler and two pharmaceutical manufacturers or other pharmaceutical manufacturers that become material to our business over time; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to effectively execute our acquisition strategy or successfully integrate acquired businesses; dependence on our senior management and key employees and managing recent turnover among key employees; potential disruption to our workforce and operations due to recent cost savings and restructuring initiatives; and the additional factors set forth in "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2016 and in subsequent reports filed with or furnished to the Securities and Exchange Commission.  Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments, or otherwise.

    Bob East, Westwicke Partners 
    443-213-0500 |

    DIPLOMAT PHARMACY, INC.Condensed Consolidated Balance Sheets (Unaudited)(dollars in thousands)June 30,December 31,ASSETS20172016Current assets:   Cash and equivalents




    7,953   Accounts receivable, net 279,604275,568   Inventories178,131215,351   Prepaid expenses and other current assets10,4776,235                    Total current assets476,016505,107Property and equipment, net20,96320,372Capitalized software for internal use, net42,95350,247Goodwill358,178316,616Definite-lived intangible assets, net195,100199,862Deferred income taxes5,0316,010Other noncurrent assets1,0811,040                    Total assets




    1,099,254LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:   Accounts payable




    320,684   Borrowings on line of credit2,52139,255   Short-term debt, including current portion of long-term debt10,8757,500   Accrued expenses:        Compensation and benefits6,5115,674        Other12,79212,233                  Total current liabilities340,417385,346Long-term debt, less current portion119,006100,184Contingent consideration4,365-                  Total liabilities463,788485,530Commitments and contingenciesShareholders' equity:   Preferred stock (10,000,000 shares authorized; none issued and outstanding)--   Common stock (no par value, 590,000,000 shares authorized; 68,017,230 and 66,764,999               shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively)515,820503,828   Additional paid-in capital35,37233,268   Retained earnings84,26476,306   Total Diplomat Pharmacy shareholders' equity635,456613,402Noncontrolling interests78322                  Total shareholders' equity635,534613,724                  Total liabilities and shareholders' equity





    DIPLOMAT PHARMACY, INC.Condensed Consolidated Statements of Operations (Unaudited)(dollars in thousands, except per share amounts)Three Months EndedSix Months EndedJune 30,June 30,2017201620172016Net sales$






    2,084,376Cost of goods sold(1,041,630)(1,005,236)(2,035,321)(1,921,868)Gross profit84,83483,270169,883162,508Selling, general and administrative expenses(79,991)(69,416)(156,492)(123,610)Income from operations4,84313,85413,39138,898Other (expense) income:Interest expense(1,931)(1,521)(3,980)(2,956)Other3410566213Total other expense(1,897)(1,416)(3,914)(2,743)Income before income taxes2,94612,4389,47736,155Income tax benefit (expense)544(4,145)(1,763)(12,679)Net income3,4908,2937,71423,476Less: net loss attributable to noncontrolling interest(101)(241)(244)(487)Net income attributable to Diplomat Pharmacy, Inc.







    23,963Net income per common share:Basic$












    0.35Weighted average common shares outstanding:Basic67,528,15166,085,14967,209,28065,312,155Diluted68,211,88268,034,39267,997,92967,939,665

    DIPLOMAT PHARMACY, INC.Condensed Consolidated Statements of Cash Flows (Unaudited)(dollars in thousands)Six Months Ended June 30,20172016Cash flows from operating activities:Net income$



    23,476Adjustments to reconcile net income to net cash provided by operating activities:     Depreciation and amortization31,93522,389     Net provision for doubtful accounts5,4014,010     Share-based compensation expense3,7983,152     Deferred income tax expense97911,178     Amortization of debt issuance costs595581     Changes in fair values of contingent consideration-(8,922)     Contingent consideration payment-(382)     Other61     Changes in operating assets and liabilities, net of business acquisitions:          Accounts receivable(3,024)(49,246)          Inventories37,179(11,358)          Accounts payable (14,353)52,878          Other assets and liabilities(2,977)(1,808)Net cash provided by operating activities67,25345,949Cash flows from investing activities:Payments to acquire businesses, net of cash acquired(53,571)(69,072)Expenditures for capitalized software for internal use(2,459)(7,349)Expenditures for property and equipment(2,289)(3,705)Other(43)1Net cash used in investing activities(58,362)(80,125)Cash flows from financing activities:Net (payments on) proceeds from line of credit(36,734)17,057Proceeds from long-term debt25,000-Payments on long-term debt(3,313)(3,000)Proceeds from issuance of stock upon stock option exercises6,0071,203Contingent consideration payment-(722)Payments of debt issuance costs-(56)Net cash (used in) provided by financing activities(9,040)14,482Net increase (decrease) in cash and equivalents(149)(19,694)Cash and equivalents at beginning of period7,95327,600Cash and equivalents at end of period




    7,906Supplemental disclosures of cash flow information:Cash paid for income taxes




    401Cash paid for interest3,3862,318

    Adjusted EBITDAThe table below presents a reconciliation of net income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA for the periods indicated.

    For the three months ended June 30,For the six months ended June 30,2017201620172016(dollars in thousands) (unaudited)Net income attributable to Diplomat Pharmacy, Inc.

    $                     3,591$                     8,534$                      7,958$                    23,963Depreciation and amortization

    16,53812,27131,93522,389Interest expense

    1,9311,5213,9802,956Income tax (benefit) expense


    $                   21,516$                   26,471$                    45,636$                    61,987Contingent consideration and other merger and acquisition expense

    $                        569$                     1,103$                      1,117$                    (7,326)Share-based compensation expense

    2,8261,6493,7983,152Employer payroll taxes - option repurchases and exercises

    1002818571Severance and related fees

    40-702-Other items

    116392544779Adjusted EBITDA

    $                   25,167$                   29,643$                    51,982$                    58,663

    Adjusted EPS (diluted)Below is a reconciliation of net income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the periods indicated. 

    For the three months ended June 30,For the six months ended June 30,2017201620172016(dollars in thousands, except per share amounts) (unaudited)Net income attributable to Diplomat Pharmacy, Inc.

    $                     3,591$                     8,534$                     7,958$                  23,963Amortization of acquisition-related intangible assets

    12,9449,81825,26518,502Contingent consideration and other merger and acquisition expense

    5691,1031,117(7,326)Income tax impact of adjustments

    (362)(3,639)(4,909)(3,731)Adjusted non-GAAP net income

    $                  16,742$                  15,816$                  29,431$                  31,408Net income attributable to Diplomat Pharmacy, Inc.

    $                       0.05$                       0.13$                       0.12$                       0.35Amortization of acquisition-related intangible assets consideration and other merger and acquisition expense tax impact of adjustments

    (0.01)(0.06)(0.08)(0.06)Adjusted EPS

    $                       0.25$                       0.23$                       0.43$                       0.46Weighted average common shares outstanding:Diluted


    2017 Full Year Guidance: GAAP to Non-GAAP ReconciliationThe tables below present a reconciliation of net income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA and net income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the year ended December 31, 2017.

    Reconciliation of GAAP to Adjusted EBITDA(dollars in thousands) (unaudited) Range LowHighNet income attributable to Diplomat Pharmacy, Inc.

    $            10,000$            16,000Depreciation and amortization

    64,66064,352Interest expense

    7,2996,999Income tax expense 


    $            85,357$            92,857Contingent consideration and other merger and acquisition expense 

    $              2,517$              2,017Share-based compensation expense

    7,2426,642Employer payroll taxes - option repurchases and exercises

    338238Severance and related fees

    1,002702Other items

    544544Adjusted EBITDA

    $            97,000$          103,000Reconciliation of GAAP to Adjusted Net Income and Adjusted EPS(dollars in thousands, except per share amounts) (unaudited) Range LowHighNet income attributable to Diplomat Pharmacy, Inc.

    $            10,000$            16,000Amortization of acquisition-related intangible assets

    49,81349,813Contingent consideration and other merger and acquisition expense 

    2,5172,017Income tax impact of adjustments 

    (13,606)(13,476)Adjusted non-GAAP net income

    $            48,724$            54,354Net income attributable to Diplomat Pharmacy, Inc.

    0.150.23Amortization of acquisition-related intangible assets

    0.730.73Contingent consideration and other merger and acquisition expense

    0.040.03Income tax impact of adjustments

    (0.21)(0.20)Adjusted EPS

    $                0.71$                0.79


    View original content with multimedia:

    SOURCE Diplomat Pharmacy, Inc.
    Copyright©2017 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Diplomat Named Among Fastest-Growing Companies in Southeast Michigan
    2. Diplomat to Release Second Quarter 2017 Operating Results and Host Conference Call on Monday, August 7, 2017
    3. Diplomat Specialty Infusion Group Now Providing Parenteral Nutrition Therapies in Iowa
    4. Diplomat Specialty Infusion Group Cincinnati Named Top Workplaces
    5. Diplomat Acquires WRB Communications
    6. Diplomat Promotes Executive Jennifer Cretu
    7. Generic Drugs Stocks on Investors Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio
    8. Dr. Regina Benjamin Appointed to Diplomats Board of Directors
    9. Diplomat to Release Fourth Quarter and Full Year 2016 Operating Results and Host Conference Call on Tuesday, February 28, 2017
    10. Diplomat Completes Acquisition of Affinity Biotech
    11. Diplomat Publishes Report on Specialty Drug Approvals
    Post Your Comments:
    (Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
    (Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
    Breaking Medicine Technology:
    (Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
    (Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
    (Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
    (Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
    Breaking Medicine News(10 mins):